Research
Molecular
Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.
Integrating various treatment modalities can enhance cost-effectiveness in obesity management.
StrongSupportsmedium confidence
Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities.
Why this rating
The claim is based on a comprehensive overview of pharmacoeconomic analyses.
Source
Obesity: Genetic Insights, Therapeutic Strategies, Pharmacoeconomic Impact, and Psychosocial Dimensions
Gladious Naguib El-hadidy et al. · Obesities · 2025
DOI 10.3390/obesities5040086
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →